Centessa Pharmaceuticals (NASDAQ:CNTA) Issues Earnings Results

Centessa Pharmaceuticals (NASDAQ:CNTA) issued its earnings results on Monday. The company reported ($0.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.38) by $0.04, Zacks reports.

Centessa Pharmaceuticals Stock Up 5.6 %

Shares of NASDAQ CNTA opened at $16.63 on Tuesday. The stock has a market capitalization of $2.19 billion, a P/E ratio of -10.87 and a beta of 1.54. The stock’s fifty day moving average is $16.49 and its 200 day moving average is $16.42. Centessa Pharmaceuticals has a 52 week low of $7.75 and a 52 week high of $19.09. The company has a debt-to-equity ratio of 0.15, a quick ratio of 21.52 and a current ratio of 21.52.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on CNTA. Morgan Stanley reissued an “overweight” rating and issued a $27.00 target price on shares of Centessa Pharmaceuticals in a research note on Friday, March 7th. TD Cowen began coverage on shares of Centessa Pharmaceuticals in a report on Tuesday, January 7th. They issued a “buy” rating for the company. Finally, Guggenheim restated a “buy” rating on shares of Centessa Pharmaceuticals in a report on Monday, February 10th. Seven analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $26.00.

Insider Activity

In related news, General Counsel Iqbal J. Hussain sold 6,000 shares of the firm’s stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $15.29, for a total value of $91,740.00. Following the completion of the transaction, the general counsel now owns 118,265 shares in the company, valued at $1,808,271.85. This trade represents a 4.83 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Gregory M. Weinhoff sold 10,000 shares of the company’s stock in a transaction that occurred on Thursday, December 26th. The shares were sold at an average price of $17.04, for a total transaction of $170,400.00. Following the completion of the transaction, the insider now owns 183,266 shares of the company’s stock, valued at approximately $3,122,852.64. This trade represents a 5.17 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 260,168 shares of company stock worth $4,316,568. 11.59% of the stock is currently owned by corporate insiders.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.